- Home
- DTSS vs BCTX Comparison
DTSS vs BCTX Comparison
Compare DTSS & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- BCTX
- Stock Information
- Founded
- DTSS 2014
- BCTX 2014
- Country
- DTSS China
- BCTX Canada
- Employees
- DTSS N/A
- BCTX N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- BCTX Health Care
- Exchange
- DTSS Nasdaq
- BCTX Nasdaq
- Market Cap
- DTSS 17.6M
- BCTX 18.5M
- IPO Year
- DTSS N/A
- BCTX N/A
- Fundamental
- Price
- DTSS $1.26
- BCTX $8.70
- Analyst Decision
- DTSS
- BCTX Strong Buy
- Analyst Count
- DTSS 0
- BCTX 1
- Target Price
- DTSS N/A
- BCTX $40.00
- AVG Volume (30 Days)
- DTSS 51.0K
- BCTX 43.9K
- Earning Date
- DTSS 11-13-2025
- BCTX 12-15-2025
- Dividend Yield
- DTSS N/A
- BCTX N/A
- EPS Growth
- DTSS N/A
- BCTX N/A
- EPS
- DTSS N/A
- BCTX N/A
- Revenue
- DTSS $64,349,277.00
- BCTX N/A
- Revenue This Year
- DTSS N/A
- BCTX N/A
- Revenue Next Year
- DTSS N/A
- BCTX N/A
- P/E Ratio
- DTSS N/A
- BCTX N/A
- Revenue Growth
- DTSS 68.56
- BCTX N/A
- 52 Week Low
- DTSS $1.03
- BCTX $6.00
- 52 Week High
- DTSS $3.10
- BCTX $190.50
- Technical
- Relative Strength Index (RSI)
- DTSS 27.94
- BCTX 42.49
- Support Level
- DTSS $1.14
- BCTX $6.93
- Resistance Level
- DTSS $1.40
- BCTX $11.54
- Average True Range (ATR)
- DTSS 0.16
- BCTX 0.77
- MACD
- DTSS -0.04
- BCTX -0.18
- Stochastic Oscillator
- DTSS 22.89
- BCTX 37.30
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.